Improved Synthesis of [F] Fallypride and Characterization of a Huntington's Disease Mouse Model, ZQ175DN KI, Using Longitudinal PET Imaging of D2/D3 Receptors

Overview

Journal EJNMMI Radiopharm Chem

Date 2019 Oct 30

PMID 31659519

Citations 5

Authors

Tuulia Huhtala

Pekka Poutiainen

Jussi Rytkonen

Kimmo Lehtimaki

Teija Parkkari

Iiris Kasanen

Anu J Airaksinen

Teija Koivula

Patrick Sweeney

Outi Kontkanen

John Wityak

Celia Dominiquez

Larry C Park

Affiliations

Soon will be listed here.

Abstract

Purpose: Dopamine receptors are involved in pathophysiology of neuropsychiatric diseases, including Huntington's disease (HD). PET imaging of dopamine D2 receptors (D2R) in HD patients has demonstrated 40% decrease in D2R binding in striatum, and D2R could be a reliable quantitative target to monitor disease progression. A D2/3R antagonist, [F] fallypride, is a high-affinity radioligand that has been clinically used to study receptor density and occupancy in neuropsychiatric disorders. Here we report an improved synthesis method for [F]fallypride. In addition, high molar activity of the ligand has allowed us to apply PET imaging to characterize D2/D3 receptor density in striatum of the recently developed zQ175DN knock-in (KI) mouse model of HD.

Methods: We longitudinally characterized in vivo [F] fallypride -PET imaging of D2/D3 receptor densities in striatum of 9 and 12 month old wild type (WT) and heterozygous (HET) zQ175DN KI mouse. Furthermore, we verified the D2/D3 receptor density in striatum with [H] fallypride autoradiography at 12 months of age.

Results: We implemented an improved synthesis method for [F] fallypride to yield high molar activity (MA, 298-360 GBq/μmol) and good reproducibility. In the HET zQ175DN KI mice, we observed a significant longitudinal decrease in binding potential (BP) (30.2%, p < 0.001, 9 months of age and 51.6%, p < 0.001, 12 months of age) compared to WT littermates. No mass effect was observed when the MA of [F] fallypride was > 100 GBq/μmol at the time of injection. Furthermore, the decrease of D2/D3 receptor density in striatum in HET zQ175DN KI was consistent using [H] fallypride autoradiography.

Conclusions: We observed a significant decrease in D2/D3R receptor densities in the striatum of HET zQ175DN KI mice compared to WT mice at 9 and 12 months of age. These results are in line with clinical findings in HD patients, suggesting [F] fallypride PET imaging has potential as a quantitative translational approach to monitor disease progression in preclinical studies.

Citing Articles

Production of [F]DPA-714, [F]fallypride and [F]LBT-999 using iMiDEV, a fully automated microfluidic platform: towards clinical radiopharmaceutical production.

Lahdenpohja S, Piatkowski C, Tanguy L, Kuhnast B EJNMMI Radiopharm Chem. 2024; 9(1):86.

PMID: 39692929 PMC: 11655818. DOI: 10.1186/s41181-024-00315-6.

Central dopamine receptors: Radiotracers unveiling the Role of dopaminergic tone in obesity.

Pais M, Crisostomo J, Abrunhosa A, Castelo-Branco M J Mol Med (Berl). 2024; 103(1):21-32.

PMID: 39630278 PMC: 11739276. DOI: 10.1007/s00109-024-02501-0.

Tetrazine Glycoconjugate for Pretargeted Positron Emission Tomography Imaging of -Cyclooctene-Functionalized Molecular Spherical Nucleic Acids.

Auchynnikava T, Aarela A, Liljenback H, Jarvinen J, Andriana P, Kovacs L ACS Omega. 2023; 8(48):45326-45336.

PMID: 38075748 PMC: 10702189. DOI: 10.1021/acsomega.3c04041.

The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?.

Lippi M, Fanelli G, Fabbri C, De Ronchi D, Serretti A Int Clin Psychopharmacol. 2022; 37(6):263-275.

PMID: 35815937 PMC: 9521590. DOI: 10.1097/YIC.0000000000000417.

Nanotechnology in Improving the Treatment of Huntington's Disease: a Systematic Review.

Valadao K, Luizeti B, Ueda Yamaguchi M, Issy A, Bernuci M Neurotox Res. 2022; 40(2):636-645.

PMID: 35060083 DOI: 10.1007/s12640-021-00468-1.

References

Ehrnhoefer D, Butland S, Pouladi M, Hayden M . Mouse models of Huntington disease: variations on a theme. Dis Model Mech. 2009; 2(3-4):123-9. PMC: 2650190. DOI: 10.1242/dmm.002451. View

Menalled L, Kudwa A, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N . Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One. 2013; 7(12):e49838. PMC: 3527464. DOI: 10.1371/journal.pone.0049838. View

Smith G, Rocha E, McLean J, Hayes M, Izen S, Isacson O . Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet. 2014; 23(17):4510-27. DOI: 10.1093/hmg/ddu166. View

Vattakatuchery J, Kurien R . Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review. World J Psychiatry. 2013; 3(3):62-4. PMC: 3832863. DOI: 10.5498/wjp.v3.i3.62. View

Niccolini F, Su P, Politis M . Dopamine receptor mapping with PET imaging in Parkinson's disease. J Neurol. 2014; 261(12):2251-63. DOI: 10.1007/s00415-014-7302-2. View

Siessmeier T, Zhou Y, Buchholz H, Landvogt C, Vernaleken I, Piel M . Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. J Nucl Med. 2005; 46(6):964-72. View

Elsinga P, Hatano K, Ishiwata K . PET tracers for imaging of the dopaminergic system. Curr Med Chem. 2006; 13(18):2139-53. DOI: 10.2174/092986706777935258. View

Heikkinen T, Lehtimaki K, Vartiainen N, Puolivali J, Hendricks S, Glaser J . Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One. 2013; 7(12):e50717. PMC: 3527436. DOI: 10.1371/journal.pone.0050717. View

Javed M, Chen S, Lei J, Collins J, Sergeev M, Kim H . High yield and high specific activity synthesis of [18F]fallypride in a batch microfluidic reactor for micro-PET imaging. Chem Commun (Camb). 2013; 50(10):1192-4. PMC: 4479166. DOI: 10.1039/c3cc47616b. View

10.

Rangel-Barajas C, Coronel I, Floran B . Dopamine Receptors and Neurodegeneration. Aging Dis. 2015; 6(5):349-68. PMC: 4567218. DOI: 10.14336/AD.2015.0330. View

11.

Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn C . PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain. 1997; 120 ( Pt 3):503-14. DOI: 10.1093/brain/120.3.503. View

12.

. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993; 72(6):971-83. DOI: 10.1016/0092-8674(93)90585-e. View

13.

Alexoff D, Vaska P, Marsteller D, Gerasimov T, Li J, Logan J . Reproducibility of 11C-raclopride binding in the rat brain measured with the microPET R4: effects of scatter correction and tracer specific activity. J Nucl Med. 2003; 44(5):815-22. View

14.

Lammertsma A, Hume S . Simplified reference tissue model for PET receptor studies. Neuroimage. 1996; 4(3 Pt 1):153-8. DOI: 10.1006/nimg.1996.0066. View

15.

Haggkvist J, Toth M, Tari L, Varnas K, Svedberg M, Forsberg A . Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex. J Nucl Med. 2016; 58(4):617-622. DOI: 10.2967/jnumed.116.180497. View

16.

Rominger A, Mille E, Zhang S, Boning G, Forster S, Nowak S . Validation of the octamouse for simultaneous 18F-fallypride small-animal PET recordings from 8 mice. J Nucl Med. 2010; 51(10):1576-83. DOI: 10.2967/jnumed.110.078451. View

17.

Mukherjee J, Yang Z, Das M, Brown T . Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol. 1995; 22(3):283-96. DOI: 10.1016/0969-8051(94)00117-3. View